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Abstract
Melatonin, a marker for the circadian rhythm with serum levels peaking between 2AM and 5AM, is hypothesized to possess
anti-cancer properties, making it a mechanistic candidate for the probable carcinogenic effect of circadian rhythm
disruption. In order to weigh epidemiologic evidence on the association of melatonin with cancer, we must first understand
the laboratory and biological sources of variability in melatonin levels measured in samples. Participants for this
methodological study were men enrolled in the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO). We
measured serum melatonin levels over a five year period in 97 individuals to test if melatonin levels are steady over time.
The Pearson correlation coefficient between two measures separated by 1 year was 0.87, while the correlation between two
measures separated by 5 years was to 0.70. In an additional cross-sectional study of 292 individuals, we used Analysis of
Variance to identify differences in melatonin levels between different lifestyle and environmental characteristics. Serum
melatonin levels were slightly higher in samples collected from 130 individuals during the winter, (6.3660.59 pg/ml) than in
samples collected from 119 individuals during the summer (4.8360.62 pg/ml). Serum melatonin levels were lowest in
current smokers (3.0261.25 pg/ml, p = 0.007) compared to never (6.6660.66 pg/ml) and former (5.5960.50 pg/ml) smokers
whereas BMI did not significantly affect serum melatonin levels in this study. In conclusion, the high 5 year correlation of
melatonin levels implies that single measurements may be used to detect population level associations between melatonin
and risk of cancer. Furthermore, our results reiterate the need to record season of sample collection, and individual
characteristics in order to maximize study power and prevent confounding.
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Introduction
Exposure to light at night has two major physiological actions: it
1) disrupts circadian rhythms and 2) suppresses the production of
melatonin [1]. In 2007, the International Agency for Research on
Cancer classified circadian rhythm disruption as a probable
carcinogen to humans [2]. Circadian disruption, is mostly
measured by shift work in epidemiologic studies, and is associated
with several cancers [3–5] including prostate [6–11], breast [12–
41], endometrium [16], ovarian [42], and colorectum [43], as well
as non-Hodgkin lymphoma [44]. However, shift work studies lack
detailed data for determining which aspects of circadian rhythm
disruption, which includes melatonin levels, work and leisure
activities, biological stress, ambient noise [45], food [46,47], and
chronotype [48], are associated with cancer risk. Incorporating
biomarkers to epidemiologic studies can help not only in
identifying the underlying mechanisms responsible for the
circadian disruption-cancer association, but also in interpreting
existing epidemiologic data [4].
Melatonin is excreted exclusively during the night by the pineal
gland [49] and exposure to light at night interrupts melatonin
secretion [50] and is associated with lower melatonin levels in
observational studies [51–55]. Additionally, melatonin can reduce
cancer cell proliferation and block cell invasion/metastasis
[56,57], providing biological plausibility to the role of melatonin
in cancer. Furthermore, concentration of the major metabolite of
melatonin, urinary 6-sulfatoxymelatonin (aMT6s), has been shown
to be inversely correlated with breast cancer risk in most studies
evaluating this association [58–62].
In addition to circadian rhythm, melatonin also displays
seasonal rhythm. Melatonin levels have been shown to be higher
during the winter in populations residing north of the 45th parallel
[51,63–69], where differences in day length between seasons are
more pronounced. However, the effect of seasons on melatonin
levels in middle latitudes, where two thirds of the world population
resides [70], is not clear. Finally, previous studies have shown that
lifestyle-related cancer risk factors, such as body mass index (BMI)
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and smoking status, also affect urinary aMT6s levels in women
[51,62,71]. However, the effects of these potential confounders
have not been evaluated in serum melatonin levels or in men.
Serum is more commonly collected in epidemiological studies
than morning urine and could be an important biologic resource
for evaluating the role of melatonin on cancer. Morning urine
aMT6s and serum melatonin levels are well-correlated [72] but
represent different aspects of the melatonin profile [73]. While
morning urine aMT6s is related to peak nocturnal melatonin
levels [74], serum melatonin reflects the amount of melatonin
circulating during the time of sample collection [73,75]. Epide-
miological studies often rely on a single serum sample commonly
collected during daylight when melatonin levels are low [76].
Since the average serum melatonin levels over time are likely to be
associated with disease, a non-representative single measurement
will reduce the study’s power to detect and quantify any tested
association using melatonin as a biomarker [77]. Additionally, it is
important to characterize the influence of possible cofounders on
serum melatonin levels. Factors possibly influencing individual
changes in melatonin levels over time that have been evaluated in
epidemiologic studies conducted to date include subject’s age and
sample storage time. Melatonin levels decrease with age
[51,62,71,78,79] and the correlation between repeated measure-
ments of aMT6s decreases as time between measurements
increases [51,69,71,80]. However, the effect of age and sample
storage time on serum melatonin levels has not yet been
quantified.
While evaluating the association of melatonin with cancer, we
need to appropriately collect, and ultimately weigh, observational
evidence [81]. Being able to use the environmental and biological
context to improve serum melatonin measurements accuracy is
crucial for building observational evidence [82]. Hence, our
objective was to determine the best approach for evaluating serum
melatonin measurements in epidemiological studies. We measured
individual serum melatonin variability over a 5 years period to
determine representativeness of a single measurement, quantified
the impact of time of the day during sample collection on study
power to identify associations between serum melatonin levels and
health outcomes, and evaluated potential confounders of these
associations, such as smoking and BMI.
Materials and Methods
Study Population
The study population consisted of 300 non-Hispanic white men
enrolled in the Prostate Lung Colorectal and Ovarian Cancer
Screening Trial (PLCO), a randomized trial designed to determine
the effectiveness of screening on cancers of the lung, prostate,
ovary and colorectum mortality. Details on PLCO study,
including Institutional Review Board approval, have been
previously published [83]. In brief, men aged 55–74 years were
randomly assigned to the screening or the control arm of the study
at 10 screening centers between 1993 and 2001. The 300
individuals in this study had no prior history of cancers and,
being in the screening trial arm of the study, had at least one
prostate cancer screen before October 1st 2003. Trial participants
are volunteers recruited from the general population in Denver
CO, Washington DC, Detroit MI, Pittsburg PA, Salt Lake City
UT, Marshfield WI, and Minneapolis MI. We do not anticipate
participation in the screening interferes with melatonin levels.
Participants were those who completed a baseline questionnaire to
elicit information on demographic characteristics and risk factors
for cancer and returned at least one annual study update. This
research was approved by the Department of Health and Human
Services Institutional Review Board. Signed informed consent was
required for eligibility.
We used stored non-fasting serum that were processed and
frozen within 2 hours of collection and stored at 270uC and
excluded 3 samples that did not reach the minimum level of
detection for the melatonin assay (0.5 pg/ml). In addition, we
excluded 5 outliers based on the definition of the following
characteristics: Cook’s distance greater than 4/n (where n is
number of observations), studentized residuals greater than 2, and
leverage greater than (2k+2)/n (where k is the number of predictor
variables and n is the number of observations). The final analytical
dataset included 292 subjects (Figure 1). Inclusion of the outliers in
the analysis did not change any of the reported associations but
yield different estimates.
To evaluate the impact of season on serum melatonin level, we
measured melatonin in baseline samples in 130 men whose blood
was collected during the winter (December through March) and
119 (no overlap) men whose samples were collected during the
summer (June through September). We focused on winter and
summer since these are the seasons with the greatest difference in
day length. All 292 subjects were included in the analysis to
evaluate the effect of time of the day during blood collection, self-
reported BMI, and smoking status (Figure 1).
To assess intra-person variation in melatonin levels over a 5-
year period, we measured serum melatonin in 97 out of the 292
subjects. These 97 subjects gave blood at four time points,
including baseline (T0), second (T2), fourth (T4) and fifth year (T5)
of the PLCO follow up study (Figure 1). To ensure that we were
evaluating individual rather than environmental variations, we
selected subjects who had blood samples collected during the same
season and at the same time of the day for all four time points for
this evaluation. In addition, we limited the subject selection to
those with all specimens collected between 7AM and 11AM, since
melatonin levels are reported to be very low in the afternoon [76].
Figure 1. Study Design. From 300 subjects enrolled in the study, 292
were selected after quality control for being included in the study. All
292 were used in the evaluation of the effects of time of the day during
sample collection, BMI, and smoking. For the evaluation of differences
in melatonin levels according to season, 130 subject whose samples
were collected during the winter and 119 subjects whose samples were
collected during the summer were selected (Total = 249 subjects).
Samples collected from 97 subjects in 4 different time points were used
to evaluate changes in melatonin levels over time.
doi:10.1371/journal.pone.0083208.g001
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Serum Melatonin Assay
Serum melatonin levels were measured using the Buhlmann
RIA kit (ALPCO, Windham NH) as previously described [72].
Briefly, 0.5 ml of serum was used for the melatonin extraction.
Melatonin was then reconstituted in assay buffer before being
quantified by Radioimmunoassay (RIA) using antiserum with an
iodinated tracer.
To evaluate technical variability, we included 2 replicate
samples from 3 individuals in each batch. Also, to minimize the
impact of assay/laboratory variation on the comparison of serum
melatonin, at the lab, we paired the 130 samples collected during
winter with the 119 samples collected during summer for the
analysis. Each pair was placed next to each other within the same
batch to minimize intra- and inter-assay variation.
In addition, for the 97 subjects with four samples from various
time points, the samples from all four time points from the same
subject were assayed within the same batch. All samples were
identified by specimen ID only so that that the lab personnel were
blinded to the status and identification of the sample.
Statistical Analysis
Melatonin Variability over Time. To assess the correlation
in melatonin levels over time (T0, T2, T4, T5), our primary
objective, we measured the unadjusted Pearson correlation
coefficient between each pair of time points (e.g. T0 vs. T2, T0
vs. T4, T0 vs. T5) among the 97 men with serial samples. We then
evaluated all time points together to obtain a single estimate of the
correlation, ru between the average melatonin levels for two
consecutive years.
To define and estimate ru we assumed that the measured log-
melatonin level, Yit, for individual i at time t is the individual’s
average log-melatonin level, Mit, plus an error term, eit, that
accounts for unmeasured short term effects (e.g. jet lag, weather,
lab error)
Yit~Mitzeit ð1Þ
We further assume that the individual’s average log-melatonin
level around time t can be described by the following function,
Mit~Pitzriznit
where Pit is ‘population’ average, ri is a subject specific effect, and
nit is the individual’s deviation from their average. We further
assume that eit, ri and nit are independent normally distributed
random variables, eit*N(0,s2e ), ri*N(0,s
2
r ) and nit*N(0,s
2
n),
and that the individual’s deviation from their own average is
correlated over time, with the correlation between years t1 and t2
defined by cor(nt1 ,nt2 )~r
Dt2{t1 D
n .
We define the ‘population’ average to be the expected log-
melatonin levels for samples that have been in storage for the same
number of years and were collected from men of the same age. Let
Ait and Sit denote age and years in storage respectively.
Pit~b0zbAAitzbSSit ð2Þ
The complete mixed model can be described by Yi. being
normally distributed with mean mi.~b0zbAAi.zbSSi. and
variance
S~s2e
1 0 0 0
0 1 0 0
0 0 1 0
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Additionally, we assessed the contribution of laboratory error to
eit. Here, we fit a mixed model with both the replicate quality
control (QC) samples and baseline samples to estimate the
intraclass correlation coefficient (ICCrep), or the correlation
between replicate measures.
The effect of batch on log-melatonin levels was tested by
ANOVA comparing models with and without batch. Mixed
models allowed for within-subject correlation, and models were fit
with only QC samples (p-value for batch = 0.51), only study
specimen (p = 0.55), and both (p = 0.79). Batch did not have a
significant effect. Thus, log-melatonin levels were not batch
adjusted.
Environmental and Behavioral Factors Influencing
Melatonin levels. To evaluate differences in melatonin levels
between environmental and behavioral characteristics, our second
objective, we used t-tests and x2 to identify differences between the
two season groups (winter N = 130 and summer N = 119) for
continuous (age) and categorical (BMI, time of the day during
blood collection, center location, and smoking) variables, respec-
tively. Since there were no differences in age, BMI, time of the day
during blood collection, and smoking between the two groups, we
used Analysis of Variance (ANOVA) to evaluate differences in
unadjusted log-melatonin levels between the winter and the
summer.
Table 1. Characteristics of the study population.
Characteristics Mean (SD)
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To evaluate how baseline log-melatonin levels varied with
respect to time of day during blood collection, BMI, and smoking
status all 292 subjects were used. Time of day during blood
collection was categorized into three blocks: 7AM–9AM, 10AM–
12PM and 1PM–4PM. We used information on self-reported BMI
and smoking status from the baseline questionnaire. BMI was
categorized into normal (18–25 kg/m2), overweight (26–30 kg/
m2), and obese (.30 km/m2), and smoking status was categorized
into never smoker, current smoker, and former smoker. We used
ANOVA to evaluate differences between each category. We also
conducted a linear regression model in order to evaluate the
relative impact of these variables on serum melatonin levels.
All data were analyzed using SAS 9.2 TS.
Estimates of power. In order to quantify how time of the
day during sample collection affects study power to detect
associations between melatonin and outcome of interest, our third
objective, we assessed the cost or benefit of a non-standard study
design with N subjects by calculating the number of subjects, Neq,
which would provide equivalent statistical power for a study design
that had one up-to-date measure per subject. We assumed the
study goal was to detect an association, or correlation, that exists
between an outcome and Mit. Furthermore, we assumed analyses
are stratified by Ait and Sit, and conditional on Mit, and that the
outcome is independent of all previous melatonin levels (i.e. no
lagged effect).
We first considered a study design that records n measurements
within a ‘‘short’’ interval for each individual. Here, for time points
t1 and t2 within a ‘‘short’’ interval we assumed cor(nt1 ,nt2 )&1 and
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Characteristics of the study population
For this study population mean age at baseline (standard
deviation) was 62.88 (3.98) years. Additionally, the majority
[N = 160 (54.98%)] of the participants were overweight, compared
to 73 (25.09%) normal weight and 58 (19.93%) obese participants.
Additionally, 168 (57.73%) of the participants were former
smokers, 96 (23.99%) never smoked, and 27 (9.28%) were current
smokers at baseline. A total of 158 (54.30%) samples were
collected between 7AM–9AM, 83 (28.52%) were collected
Figure 2. Sources of serum melatonin levels variability. A. Melatonin levels were higher during the winter [Mean= 6.36 (Standard Error of the
Mean=0.57) pg/ml, n = 130], although not statistically significantly different (PMANOVA = 0.07) than summer values [4.83 (0.60) pg/ml, n = 119]. B. Mean
serum melatonin levels were highest [7.86 (0.70 pg/ml), n = 158] in early morning 7AM–9AM, twice as high as serum melatonin levels collected
between 10AM–12PM [3.92 (0.79) pg/ml, n = 83] and three times higher than samples collected between 1PM–4PM [2.22 (0.89) pg/ml, n = 50]
(PANOVA,0.001). C. Melatonin levels were lowest in current smokers [3.02 (1.25) pg/ml, n = 96, PANOVA = 0.007] compared to never smokers and former
smokers [6.66 (0.66) pg/ml, n = 27, and 5.59 (0.50) pg/ml, n = 168, respectively]. D. BMI was not associated with melatonin levels (PANOVA = 0.059),
being similar between normal weight [5.12 (0.76) pg/ml, n = 72], overweight [5.24 (0.51) pg/ml, n = 216], and obese [7.77 (0.86) pg/ml, n = 100]
subjects.
doi:10.1371/journal.pone.0083208.g002
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between 10AM–12PM, and 50 (17.18%) were collected between
1PM–4PM. Finally, 130 (44.67%) samples were collected during
the winter, 32 (11.00%) were collected during the spring, 119
(40.89%) were collected during the summer, and 10 (3.44%) were
collected during the fall (Table 1).
Melatonin Variability over Time
The variability of melatonin over time was assessed using 97
men aged 55 to 71 with samples collected at 4 time points (T0, T2,
T4, and T5). The samples used in this analysis were in storage for
between 4 and 15 years. The average correlation coefficient (95%
Confidence Interval) for measurements separated by 1, 2, 4, and 5
years were 0.87 (0.81, 0.91), 0.80 (0.72, 0.86), 0.73 (0.63, 0.81),
and 0.70 (0.59, 0.79) respectively, suggesting a reduction in
correlation over time. Only a small proportion of the short-term
variability is attributable to laboratory variability, ICCrep = 0.98
(0.005).
We estimated the short-term and long-term variability by fitting




r^n~0:86(SE~0:13). A small proportion of variability
(11% = 0.05/0.46) can be attributed to short term changes in
individual’s melatonin level. These estimates suggest that the
correlation between measurements taken at intervals of 1 year, 2
years, 5 years, and 10 years should be. 0.83, 0.78, 0.68, and 0.58.
Factors which could influence changes in melatonin levels
during a 5 year period include, but are not limited to, age of the
individual and sample storage time. For samples stored over the
same time period, melatonin levels were expected to decrease by
approximately 3% for each additional year of age
(b
_
A~{0:030 (0:012), equation 2). For samples from individual(s)
of the same age, melatonin levels were expected to decrease by
3.8% (b
_
S~{0:038 (0:015)) for each additional year of storage.
Environmental and Behavioral Factors
Serum melatonin levels were slightly higher in the 119 samples
collected during the winter [6.36 (0.59) pg/ml] compared to the
130 collected during the summer [4.83 (0.62) pg/ml], although
this difference was not statistically significant (PANOVA = 0.07)
(Figure 2A). There were no differences in age, time of blood
collection, BMI, or smoking history between the 130 and 119
subjects who had blood collected in winter or summer (Table S1).
The effects of time of day during blood collection, smoking, and
BMI were assessed using the baseline measures in 292 men. As
expected, serum log-melatonin levels decreased significantly with
increasing time of day. Melatonin levels [mean (standard error of
the mean)] were highest in serum collected in the early morning
7AM–9AM [7.86 (0.70) pg/ml, n = 158, PANOVA,0.001], twice as
high as serum collected in the 10AM–12PM [3.92 (0.79) pg/ml,
n = 83) period, and three times higher than serum collected in the
1PM–4PM period [2.22 (0.89) pg/ml, n = 50] (Figure 2B).
In addition, mean (SEM) serum melatonin levels were lowest in
current smokers [3.02 (1.25) pg/ml, n = 96, PANOVA = 0.007),
compared to never smokers [6.66 (0.66) pg/ml, n = 27], and
former smokers [5.59 (0.50) pg/ml, n = 168) (Figure 2C). Serum
melatonin levels were similar in normal weight and overweight
subjects [5.12 (0.76) pg/ml, n = 72 and 5.24 (0.51) pg/ml, n = 216,
respectively), and slightly higher in obese subjects [7.77 (0.86) pg/
ml, n = 100, PANOVA = 0.06] (Figure 2D).
Similarly, when evaluating the relative impact of these variables,
time of the day during sample collection had the greatest effect on
serum melatonin level (b=24.00 and 25.44 for samples collected
between 10AM–12PM and 1PM–4PM compared to 7AM–9AM).
Smoking also had a significant relative effect (b=23.16 for
current smokers compared to never smokers). The effects of BMI
and season on melatonin levels were not significant (Table 2).
Estimates of Power
Given the low contribution of short term effects to intra-
individual melatonin levels variability, measuring melatonin in two
samples collected within a short time period (,1 year) offers
minimal improvement to the power of a study. However, since
serum melatonin levels decrease in samples that have been stored
for longer periods, measuring melatonin in samples that have been
collected more recently provides more power to identify associ-
ations between melatonin levels and outcomes of interest. For
example, compared to 50 samples stored for less than one year, 50
samples that have been stored for 5 or 10 years would be
equivalent to 23 or 17 samples, respectively. Depending on the risk
ratio of the outcome of interest (2, 3, or 4, for example), using
samples stored for less than one year would increase the power of
the study by 1.56, 1.42, and 1.26 times, respectively (Figure 3A).
The differences in melatonin levels according to lifestyle
characteristics and environmental factors were more easily
detectable when samples were collected before 9AM (Table S2).
In order to evaluate the effect of time of the day during sample
collection on study power, we used smoking as example of the
variable of interest. The mean (standard deviation) serum
melatonin levels in never smokers and current smokers measured
between 7AM and 9AM were 10.16 (8.15) pg/ml and 2.03 (2.52)
pg/ml. In contrast, the levels measured between 1PM and 4PM
were 2.21 (0.99) pg/ml for current smokers and 2.30 (1.81) pg/ml
in never smokers. Given these estimates, 14 subjects would be
needed to have 80% power to detect the effect of smoking in
samples collected before 9AM, while 15,032 subjects would be
needed if samples were collected between 1PM and 4PM
(Figure 3B).
Table 2. Relative impact of environmental and behavioral
factors on serum melatonin levels.
Variable b SE P
Intercept 11.07 6.01 ,0.0001
Age 20.04 0.10 0.11
Smoking
Current 23.16 1.34 0.003
Former 21.11 0.79 0.11
BMI
Overweight 0.47 0.88 0.99
Obese 2.51 1.10 0.09
Time
10AM–12PM 24.00 0.85 ,0.0001
1PM–4PM 25.44 1.02 ,0.0001
Season
Spring 22.15 1.26 0.19
Summer 21.01 0.78 0.68
Fall 20.88 2.04 0.77
BMI = Body Mass Index (kg/m2).
Time= Time of the day during sample collection.
Age modeled as a continuous variable.
Never smoker, normal weight, 7AM–9AM, and winter used as reference groups
for smoking, BMI, Time, and season, respectively.
doi:10.1371/journal.pone.0083208.t002
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Discussion
In this study of healthy non-Hispanic white males, we showed
that 1) correlation of intra-individual serum melatonin levels
decreases over a 5 year period, 2) identifying differences in serum
melatonin levels between individuals is easier in samples collected
before 9AM, and 3) smoking status affect serum melatonin levels in
men.
To our knowledge, this is the first study to evaluate long-term
intra-person variation in serum melatonin levels and its impact on
future studies of disease-melatonin associations. Furthermore, we
assessed the role of lifestyle and environmental factors in that
variation.
The correlation between serum melatonin levels decreased over
time, concordant with urinary aMT6S measurements, where the
correlation decreases from r = 0.85 over 72 hours to [69,84]
r = 0.75 in 6 months [51], r = 0.72 in 3 years, [71], and r = 0.56 in
5 years [80]. Factors influencing individual changes in melatonin
levels over time include the subject’s age and sample storage time.
Serum melatonin levels decreased with advancing age at rates
similar to that reported in cross-sectional studies [51,62,71,78,79],
and melatonin levels decreased with increasing number of years in
storage. Progressive degradation associated with long-term sample
storage has only recently been reported [85], and its role on
melatonin measurements has not been studied. These results
suggest that epidemiologic studies evaluating the role of melatonin
in cancer etiology should match on individual’s age and sample
storage time in order to minimize bias. Additionally, while
measuring multiple samples collected at least 5 years apart can
increase study power, laboratory variability was minimal, indicat-
ing that one measurement is representative of melatonin levels at a
single time point.
Similar to studies conducted in Nordic latitudes [51,63–67],
where differences in day length between seasons is more
pronounced than in tropical latitudes, we found that melatonin
levels were slightly higher during the winter. During the winter,
melatonin circadian rhythm also displays a phase shift towards the
morning hours [63,64,66,67,86–88], with shorter duration of
melatonin excretion [79] which could attenuate seasonal differ-
ences in melatonin levels if samples are collected in the morning,
as they were in our study.
Figure 3. Determinants of study power. A. Study power decreases with increasing sample storage time (&0 years, m 5 years, N10 years). The
curves show the corresponding power of a study (n = 50) for each magnitude of relative risk of disease when comparing the highest quartile of
melatonin level to the lowest quartile. B. Required sample size for detecting differences between subjects is smaller if blood is collected before 9AM
(14 men) compared to 10AM–12PM (172 men) and 1PM–4PM (15032 men). Data shown as Mean (Standard Error of the Mean).
doi:10.1371/journal.pone.0083208.g003
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In epidemiologic studies, melatonin is traditionally measured
using first-void urinary aMT6s, which reflects melatonin levels
during the night [89]. There is good correlation between urine
aMT6s and serum melatonin levels [72] and blood samples, not
first-void urine, are routinely collected in epidemiology studies.
Our data suggest that for studies that measured serum melatonin
during the day, it is best to use samples collected in early morning
(e.g. before 9AM), when melatonin levels are reasonably high and
allow for evaluating differences between individuals, as indicated
by our power analysis. Concordant with previous studies which
have reported that serum melatonin levels measured in samples
collected after 10AM cannot be used as a biomarker for sleep
duration [90] or exposure to light at nigh [91], we do not
recommend using samples collected after 10AM. Samples
collected after 10AM are problematic because the individual
variation might be smaller than the assay technical variation..
Finally, epidemiology studies should always consider time of the
day during blood collection when evaluating associations with
serum melatonin levels.
Smoking status was the only variable to have a significant
relative impact on melatonin variability when all environmental
and behavioral characteristics were evaluated together with time
of the day during sample collection. Our results show that male
current smokers had melatonin levels that were 50% those of
former and never smokers, similar to the ratio previously reported
for healthy adult women [71,92]. This is the largest study to date
to evaluate melatonin levels associated with smoking status in men
[93] and these results need to be replicated in larger studies.
In this population of healthy adult men, melatonin levels were
slightly higher in obese men, similar to results presented in a recent
study [94] and two early small studies [95,96]. This positive
association between melatonin and BMI in males is intriguing,
since an inverse association is observed in women
[51,62,71,84,97]. The relationship between melatonin levels and
BMI has been shown to be gender specific in pubertal individuals,
where boys displayed a positive association between BMI and
melatonin levels [98]. Further studies with larger sample of males
are required to clarify the association, if any, between melatonin
and BMI in men.
Our study has several limitations. Although we included more
than 200 samples for the assessment of seasonal variation, our
sample size is still limited. Additionally, self-reported BMI is
subject to misclassification [99], and the well-known downward
bias in self-reported BMI could have attenuated our results. For
the melatonin variability over time analysis, BMI and smoking
status were only assessed at baseline and might have changed
during the five years of follow up. Hence, we were unable to
account for potential differences in melatonin levels due to changes
in BMI and smoking status through time. Finally, our data are
limited to non-Hispanic whites, and patterns in melatonin levels
need to be investigated further in other ethnicities.
Strengths of the study should be noted. We were able to identify
the contribution of assay reliability, sample storage time, and
lifestyle characteristics to intra-individual variation in serum
melatonin levels over time. Accuracy in estimating intra-individual
variability was increased by collecting samples during the same
season and time of day at all time points for each individual. Also,
this is the largest study to evaluate differences in serum melatonin
levels due to smoking and BMI in healthy males [95,96] to date.
Previous studies have focused mainly in women [14,51,62,84,97].
In summary, our results provide important insight for accurately
measuring melatonin levels in previously collected serum samples.
Future study designs should consider our results, as well as the fact
that serum melatonin levels reflect the amount of circulating
melatonin at the time of sample collection and is not a
comprehensive biomarker for the different aspects of the
melatonin profile [73], to appropriately address their research
question.
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